INVESTORS & MEDIA
News Release
Regeneron Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference
About Regeneron
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Contact Information:
Investor Relations
914.847.3482
mark.hudson@regeneron.com
Corporate Communications
914.847.8827
christina.chan@regeneron.com
View original content:https://www.prnewswire.com/news-releases/regeneron-announces-presentation-at-the-40th-annual-jp-morgan-healthcare-conference-301449888.html
SOURCE